Cravath Publishes Summer 2026 Issue of Alumni Journal
Joyce Law is the senior lead attorney in the Firm’s real estate practice. Ms. Law concentrates her practice on real estate development, acquisitions and dispositions, as well as real estate financing, including fund credit facilities and municipal financings, real estate fund work and leasing transactions. Ms. Law also regularly assists on the real estate aspects of various corporate mergers and acquisitions.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law is from Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was named a senior attorney in 2015 and of counsel in 2025. Prior to joining Cravath, she was associated with a real estate developer in New York.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law is from Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was named a senior attorney in 2015 and of counsel in 2025. Prior to joining Cravath, she was associated with a real estate developer in New York.
Education
-
J.D., 1997, Boston University School of Law
-
B.Comm., 1994, University of AlbertaDistinction
Admitted In
- New York
Deals & Cases
October 29, 2026
ADT’s $15.3 Billion Acquisition by Thrive Holdings
On October 29, 2026, ADT Inc. (“ADT”), a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., and Thrive Holdings, a permanent capital holding company focused on investing in established businesses and advancing their capabilities through technology, announced a definitive agreement under which Thrive Holdings will acquire ADT in an all‑cash transaction. The agreement values ADT at approximately $7.6 billion in equity value and $15.3 billion in enterprise value. Under the terms of the agreement, which ADT’s Board of Directors unanimously approved, ADT stockholders will receive $10.00 per share in cash upon completion. Following completion, ADT will become privately held and its common stock will cease trading on the New York Stock Exchange. Cravath is representing ADT in connection with the transaction.
Deals & Cases
October 29, 2026
Instacart’s $17 Billion Acquisition by DoorDash
On October 29, 2026, DoorDash, Inc. (“DoorDash”) and Maplebear Inc. (d.b.a. Instacart) (“Instacart”) announced a definitive agreement under DoorDash will acquire Instacart for a total value of $65.00 for each Instacart share, or an equity value of approximately $17 billion. The aggregate transaction consideration will be at least 75% cash, with Instacart stockholders able to elect cash, DoorDash stock, or a combination of both, subject to proration so that DoorDash stock does not exceed 25% of the aggregate consideration. Instacart's board of directors has unanimously approved the agreement. Cravath is representing Instacart in connection with the transaction.
Deals & Cases
October 20, 2026
Neurotech’s Acquisition by Alcon
On October 20, 2026, Alcon, a global leader in eye care, announced it has acquired Neurotech Pharmaceuticals, Inc. (“Neurotech”), a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases, for $550 million. Alcon may be required to make additional contingent payments, including upon the achievement of commercial milestones. This acquisition expands Alcon's retina portfolio with ENCELTO™, the first and only U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (“MacTel”), a rare, progressive retinal disease that leads to irreversible central vision loss that has historically had no approved treatment options. Cravath represented Neurotech in connection with the transaction.
Deals & Cases
October 08, 2026
Viatris’s $1.65 Billion Acquisition of Pacira
On October 8, 2026, Viatris Inc. (“Viatris”), a global healthcare company, and Pacira BioSciences, Inc. (“Pacira”), a leader in innovative non‑opioid pain therapies, announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Cravath is representing Viatris in connection with the transaction.
Deals & Cases
October 01, 2026
Corteva’s Spin‑Off of Seed and Genetics Business
On October 1, 2026, Corteva, Inc. (“Corteva”) announced it has successfully spun off its advanced seed and genetics business as a new public company, Vylor, Inc., and will move forward as a leading, pure‑play global crop protection company. Cravath is representing Corteva in connection with the transaction.
Firm News
November 20, 2025
Cravath Announces New Partners and Of Counsels
Cravath has elected the following new partners, who will become members of the Firm on January 1, 2026:
Joyce Law is the senior lead attorney in the Firm’s real estate practice. Ms. Law concentrates her practice on real estate development, acquisitions and dispositions, as well as real estate financing, including fund credit facilities and municipal financings, real estate fund work and leasing transactions. Ms. Law also regularly assists on the real estate aspects of various corporate mergers and acquisitions.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law is from Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was named a senior attorney in 2015 and of counsel in 2025. Prior to joining Cravath, she was associated with a real estate developer in New York.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law is from Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was named a senior attorney in 2015 and of counsel in 2025. Prior to joining Cravath, she was associated with a real estate developer in New York.
Education
-
J.D., 1997, Boston University School of Law
-
B.Comm., 1994, University of AlbertaDistinction
Admitted In
- New York
Deals & Cases
October 29, 2026
ADT’s $15.3 Billion Acquisition by Thrive Holdings
On October 29, 2026, ADT Inc. (“ADT”), a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., and Thrive Holdings, a permanent capital holding company focused on investing in established businesses and advancing their capabilities through technology, announced a definitive agreement under which Thrive Holdings will acquire ADT in an all‑cash transaction. The agreement values ADT at approximately $7.6 billion in equity value and $15.3 billion in enterprise value. Under the terms of the agreement, which ADT’s Board of Directors unanimously approved, ADT stockholders will receive $10.00 per share in cash upon completion. Following completion, ADT will become privately held and its common stock will cease trading on the New York Stock Exchange. Cravath is representing ADT in connection with the transaction.
Deals & Cases
October 29, 2026
Instacart’s $17 Billion Acquisition by DoorDash
On October 29, 2026, DoorDash, Inc. (“DoorDash”) and Maplebear Inc. (d.b.a. Instacart) (“Instacart”) announced a definitive agreement under DoorDash will acquire Instacart for a total value of $65.00 for each Instacart share, or an equity value of approximately $17 billion. The aggregate transaction consideration will be at least 75% cash, with Instacart stockholders able to elect cash, DoorDash stock, or a combination of both, subject to proration so that DoorDash stock does not exceed 25% of the aggregate consideration. Instacart's board of directors has unanimously approved the agreement. Cravath is representing Instacart in connection with the transaction.
Deals & Cases
October 20, 2026
Neurotech’s Acquisition by Alcon
On October 20, 2026, Alcon, a global leader in eye care, announced it has acquired Neurotech Pharmaceuticals, Inc. (“Neurotech”), a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases, for $550 million. Alcon may be required to make additional contingent payments, including upon the achievement of commercial milestones. This acquisition expands Alcon's retina portfolio with ENCELTO™, the first and only U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (“MacTel”), a rare, progressive retinal disease that leads to irreversible central vision loss that has historically had no approved treatment options. Cravath represented Neurotech in connection with the transaction.
Deals & Cases
October 08, 2026
Viatris’s $1.65 Billion Acquisition of Pacira
On October 8, 2026, Viatris Inc. (“Viatris”), a global healthcare company, and Pacira BioSciences, Inc. (“Pacira”), a leader in innovative non‑opioid pain therapies, announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Cravath is representing Viatris in connection with the transaction.
Deals & Cases
October 01, 2026
Corteva’s Spin‑Off of Seed and Genetics Business
On October 1, 2026, Corteva, Inc. (“Corteva”) announced it has successfully spun off its advanced seed and genetics business as a new public company, Vylor, Inc., and will move forward as a leading, pure‑play global crop protection company. Cravath is representing Corteva in connection with the transaction.
Firm News
November 20, 2025
Cravath Announces New Partners and Of Counsels
Cravath has elected the following new partners, who will become members of the Firm on January 1, 2026:
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.